A combination of atezolizumab and bevacizumab demonstrated favourable progression-free survival (PFS) in patients with treatment-naïve advanced or metastatic renal cell carcinoma (RCC), particularly those with PD-L1-positive disease, findings from the phase III IMmotion151* trial show.
Enzalutamide may improve the rate of achieving prostate-specific antigen (PSA) remission and consequently, survival outcomes among prostate cancer patients, according to studies presented at the ASCO Genitourinary (ASCO GU) Cancers Symposium 2018.
Long-term data from the KEYNOTE-045 trial showed ongoing superiority of the programmed death 1 (PD-1) inhibitor pembrolizumab compared with chemotherapy for advanced and metastatic bladder cancer, according to results presented at the ASCO Genitourinary Cancers Symposium 2018 (ASCO GU 2018).
Abiraterone acetate (AA) was associated with improved survival outcomes in prostate cancer treatment and had a favourable toxicity profile, according to several studies presented at the ASCO Genitourinary Cancers Symposium 2018 (ASCO GU 2018).
The androgen receptor inhibitor apalutamide prolonged metastasis-free survival (MFS) by approximately 2 years in men with nonmetastatic castration-resistant prostate cancer (nmCRPC) who are at high risk of metastatic disease, according to findings of the SPARTAN* trial.
Combining axitinib with pembrolizumab results in an “unprecedented” objective response rate (ORR) in treatment-naïve patients with advanced renal cell carcinoma (RCC), results of an ongoing phase Ib trial have shown.
Chinese patients with metastatic castration-resistant prostate cancer (mCRPC) have higher response rates, longer survival and a lower risk of fatigue when enzalutamide is used in earlier rather than later lines of treatment, a study by the Hong Kong Society of Uro-Oncology has shown.
Asia's trusted medical magazine for healthcare professionals.
Get your MIMS Oncology - Malaysia digital copy today!
Dr. Jay Zhu, Dr. Lai Fung Li, Prof. Chae-Yong Kim,
27 Nov 2019
The current standard
of care for glioblastoma multiforme (GBM), an aggressive primary brain tumour
with a rapid disease course, consists of maximum safe surgical resection
followed by radiotherapy with concomitant temozolomide (TMZ) chemotherapy and
subsequent TMZ maintenance. At the 16th Annual Meeting of the Asian
Society of Neuro-Oncology (ASNO) in Taipei, Taiwan, experts reviewed the
evidence and shared their clinical experience on the use of tumour treating
fields (TTFields), a novel treatment modality for GBM.